Everlywell rolls out Clairity AI for breast cancer in US
Digital health firm Everlywell is rolling out a Clairity AI, which can assess the risk of developing breast cancer from a mammogram, across the US.
Newsletters and Deep Dive digital magazine
Digital health firm Everlywell is rolling out a Clairity AI, which can assess the risk of developing breast cancer from a mammogram, across the US.
The UK is putting £80 million ($105 million) in funding behind nine technologies that it hopes will be able to diagnose dementia more quickly.
Industry must build custom solutions that leverage a pharmaceutical business’ unique assets – including its people.
An AI system can be cheap to buy and expensive to stop.
The infiltration of Australia's Medicare by an AI agent raises serious questions about patient privacy and the security of confidential pharma data.
Editor's Picks
Newsletters and Deep Dive
digital magazine